Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy.
about
Benign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus InfectionHepatitis C virus reactivation in cancer patients in the era of targeted therapies.The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development.Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infectionHCV infection, B-cell non-Hodgkin's lymphoma and immunochemotherapy: Evidence and open questions.'Les liaisons dangereuses': Hepatitis C, Rituximab and B-cell non-Hodgkin's lymphomas.Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV InfectionInfectious complications associated with monoclonal antibodies and related small moleculesThe late adverse events of rituximab therapy--rare but there!Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana LinfomiReactivation of hepatitis B virus and hepatitis C virus in patients with cancer.Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy.The past, present and future of neutralizing antibodies for hepatitis C virus.Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatmentThe influence of rituximab-containing chemotherapy on HCV load in patients with HCV-associated non-Hodgkin's lymphomas.Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study.Hepatitis C in haematological patients.Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy.Do hepatitis C Virus genotypes influence liver dysfunction following rituximab-containing regimens in patients with diffuse large B cell lymphoma?Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy.Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy.A comparison of safety profiles of tumour necrosis factor α inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C.Impact of Immunochemotherapy-Related Hepatic Toxicity on the Outcome of HCV-Positive Diffuse Large B-Cell Lymphoma Patients
P2860
Q26775733-B4F647FB-9570-4E76-952A-3477B0BD52C8Q33735212-126E160F-C38E-46AE-9F3E-0C8630EA44DBQ34481429-86E235C3-DD5E-48A7-9E33-D38FF815706DQ35731058-51E06B11-92D6-4B8B-A975-C25111CC7C11Q35854495-7A6BC393-0769-403C-A975-1074035DF594Q35948807-10C2CB0D-B9EF-4CF2-BDDC-C8040046E36CQ36811958-044DFCFD-52C5-4810-A4AD-7757D2C5D61DQ37156636-2A845275-DA31-4A42-B084-0A8B742963CDQ37462485-05E80879-192C-442E-A425-81B5399EE8B3Q37618904-BE72BC46-940E-4581-ABCF-038CE99311BDQ37978202-6FE6F149-C088-4097-AFA0-2826ABAEB415Q38062943-60B6CF14-24AF-45B4-9B6A-7163661E4D8CQ38192357-89BFD9F1-DDDD-436A-8A07-97E1EBAC2695Q38244519-FD66A7D8-370E-4BC3-BC8E-989EDFD676A2Q40138130-5ECB469A-E786-477A-93A2-D09E4A11ADB2Q40144152-AEB9E0B6-AE23-46C2-95EB-A51A40199A7DQ41218951-CFE15138-6E99-4AE6-8B9E-31DFA005E779Q42210964-686C955C-7B89-4B85-8556-0EDA5E82E5FDQ42977816-3DE3A82C-61CC-4A63-8102-91044FD29F2AQ43040370-43E27ADA-72BE-4EE6-8C2A-1FE186B1ACEEQ47564274-B28BB5ED-720A-44D3-82A2-39955CDEBD11Q48163642-557052EF-8587-4A14-9B4D-29D054EC5C8EQ59052762-09CC002E-D689-459F-98A2-BFB2FFC7DCA7
P2860
Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Monitoring serum hepatitis C v ...... imab combination chemotherapy.
@en
Monitoring serum hepatitis C virus
@nl
type
label
Monitoring serum hepatitis C v ...... imab combination chemotherapy.
@en
Monitoring serum hepatitis C virus
@nl
prefLabel
Monitoring serum hepatitis C v ...... imab combination chemotherapy.
@en
Monitoring serum hepatitis C virus
@nl
P2093
P50
P356
P1476
Monitoring serum hepatitis C v ...... imab combination chemotherapy.
@en
P2093
Daisuke Ennishi
Kiyohiko Hatake
Masahiro Yokoyama
Shunji Takahashi
Yasuhito Terui
Yuko Mishima
P356
10.1002/AJH.21022
P577
2008-01-01T00:00:00Z